Riskpilot← Back to searchSign inGet full accessENDOMED AS
ASActiveOrg 813165082Professor Birkelands Vei 34B, 1081 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 19763 employees
Revenue 2024
NOK 30,2M
+9% vs 2023
EBITDA margin
14.9%
+85% vs 2023
Equity ratio
40.3%
Financial strength
Net profit 2024
NOK 3,4M
+100% vs 2023
| Revenue | NOK 30,2M | +9% |
| EBITDA | NOK 4,5M | +85% |
| Net profit | NOK 3,4M | +100% |
| Total assets | NOK 12,6M | +23% |
| Equity | NOK 5,1M | +8% |
| Employees | 3 | — |
Legal name
ENDOMED AS
Org number
813165082
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29. oktober 1976
Share capital
NOK 1 250 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Address
Professor Birkelands Vei 34B, 1081 Oslo
Email
email@endomed.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 17 388 | 19 067 | 24 940 | 27 771 | 30 173 |
| Staff expenses | −3 197 | −3 351 | −2 841 | −3 671 | −3 374 |
| EBITDA | 1 154 | 1 997 | 3 561 | 2 431 | 4 489 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −1 |
| EBIT | 1 154 | 1 997 | 3 561 | 2 431 | 4 487 |
| Net financials | −39 | −47 | −135 | −247 | −139 |
| Profit before tax | 1 115 | 1 950 | 3 426 | 2 184 | 4 348 |
| Tax | 246 | 429 | 756 | 494 | 961 |
| Net profit | 868 | 1 521 | 2 669 | 1 690 | 3 387 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 191 | 8 948 | 11 393 | 10 177 | 12 568 |
| Equity | 4 673 | 4 678 | 4 678 | 4 678 | 5 064 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 517 | 4 270 | 6 715 | 5 499 | 7 503 |
| Total debt | 3 517 | 4 270 | 6 715 | 5 499 | 7 503 |
EBITDA margin
14.9%
This company
15.8%
Market median
-6% vs market
20202024
Equity ratio
40.3%
This company
38.2%
Market median
+5% vs market
20202024
Return on equity
66.9%
This company
18.4%
Market median
+264% vs market
20202024
Net profit margin
11.2%
This company
8.1%
Market median
+38% vs market
20202024
Asset turnover
2.40×
This company
1.12×
Market median
+114% vs market
20202024
Debt / equity
1.48×
This company
0.62×
Market median
-139% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
VB Deputy Member | Deputy Member | 2019 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (2) | ||
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2023 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 95.62% | 95.62% | 2024 | |
| Individual | 4.38% | 4.38% | 2024 | |
| Individual | 2.47% | 2.47% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Capitol Ii As
ENDOMED AS Board members of ENDOMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vibeke Birkeli | Deputy Member | 0 companies |
| Joachim Christian Meinich Frich | Board of Directors | 0 companies |
| Sverre Frich | Chairman | 0 companies |
| Erik Storbekken | Board of Directors | 0 companies |
| Rolf Askvig Engelhardtsen | Board of Directors | 0 companies |